# RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma

> **NCT01047293** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Utah** · enrollment: 47 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** RAD001
- **DRUG:** FOLFOX
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01047293
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2017-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01047293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01047293, "RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01047293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*